CoreAge Rx vs Vea Health
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
CoreAge Rx
Best for: semaglutide at $99/month, 48% under the register median
Visit CoreAge Rx →
Vea Health
Best for: coverage in all 50 states, which most of the register will not confirm
Visit Vea Health →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, CoreAge Rx starts at $99/mo, and CoreAge Rx finishes ahead, 9.1 to 4.7. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
CoreAge Rx
Re-verified 2026-08-05: homepage + Preventive Longevity section both show "Semaglutide — Starting at $99/mo", "Same price at every dose"; supersedes stale tiered pricing captured 2026-06-05.
Re-verified 2026-08-05: homepage GLP-1 hero + Preventive Longevity section both show "Tirzepatide — Starting at $149/mo", "Same price at every dose"; supersedes stale tiered pricing captured 2026-06-05.
Vea Health
Pricing not publicly listed.
What’s included
CoreAge Rx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Vea Health
Inclusions not disclosed.
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
CoreAge Rx
9.1/10
Vea Health
4.7/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | CoreAge Rx | Vea Health |
|---|---|---|
| Starting Price | $99/mo | — |
| Features | 6 features | ✓7 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | — |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About CoreAge Rx
Shipping is free, 2-day, and reaches all 50 states. CoreAge Rx sells LegitScript-verified compounded semaglutide plus tirzepatide, with licensed physicians behind it and 24/7 support. Its own claim: nobody in the compounded GLP-1 space prices more competitively.
Read our full CoreAge Rx review →About Vea Health
Vea Health does not show pricing publicly; it is gated behind sign-up. The platform targets men's health, performance and longevity, selling compounded semaglutide and tirzepatide in both oral and injection protocols, and publishes a clear FDA compounded-medication disclaimer. That dual oral-and-injection lineup is its differentiator. The platform says it serves all 50 states via a clinician network.
Read our full Vea Health review →Pros & Cons
CoreAge Rx
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $149 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Vea Health
What we like
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
Our Verdict
CoreAge Rx takes it, 9.1 against 4.7, and it is especially strong on semaglutide at $99/month, 48% under the register median. Vea Health is no weak second and may fit you better on coverage in all 50 states, which most of the register will not confirm.
Choose CoreAge Rx if…
You want semaglutide at $99/month, 48% under the register median and an opening price near $99 a month.
Choose Vea Health if…
You want coverage in all 50 states, which most of the register will not confirm.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →Direct Meds
Compounded semaglutide at $249/month
From $249/mo
Get started →Try Ageless
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →CoreAge Rx vs Vea Health: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring CoreAge Rx and Vea Health head-to-heads in the same category.
- CoreAge Rx vs Trimi Health
- CoreAge Rx vs Embody
- CoreAge Rx vs He & She MD
- Vea Health vs Lean Meds
- Vea Health vs NextMeds
- Vea Health vs bmiMD
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.